ArticleScientific reports2025
Nomogram construction and survival analysis in T3N0M0 breast cancer: a SEER population-based analysis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Breast cancer, a heterogeneous disease, is notable for its high morbidity, recurrence, and mortality. T3N0M0 is controversial in terms of clinical prognosis and therapeutic decision-making. We collected baseline and treatment information on patients with T3N0M0 between 2010 and 2015 from the Surveillance, Epidemiology, and End Results programme (SEER) database. Univariate analyses of clinicopathological characteristics were performed using the log-rank test, while variables that were statistically significant (p < 0.05) were included in multivariate analyses to identify prognostic risk factors included in the construction of nomograms. Receiver operating characteristic (ROC) curves, calibration curves and decision curve analysis (DCA) curves were applied to evaluate the nomogram. We obtained a total of 4,641 patient clinical characteristics from the SEER database. In T3N0M0 group, the overall survival (OS) for 3, 5 and 10 years was 87.1%, 79.5% and 71.6%, and breast cancer-specific survival (BCSS) was 92.0%, 88.1% and 85.3%, respectively. We ultimately identified eight variables (age, grade, surgery, radiation, chemotherapy, ER-status, PR-status, Her2-status) were associated with OS while seven variables (age, grade, surgery, radiation, chemotherapy, PR-status, Her2-status) were associated with BCSS. The nomogram was constructed based on independent prognostic risk factors, the area under the curve (AUC) values were well performed, the ROC curves, calibration curves and DCA curves all indicated that the nomogram had better clinical practicability. The current study provides a new clinical assessment tool for T3N0M0 breast cancer patients, as well as a reference for clinicians in selecting management decisions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.